Related coverage linked through entity extraction aliases.
Jul 21, 2026
New studies link GLP-1 drugs to eating disorders, erectile dysfunction and relationship changes, while Deloitte reports the drugs' market boom has lifted pharma R&D returns but created a concentration risk.
Aug 08, 2026
A Cochrane review found intermittent fasting did not beat standard diet advice for weight loss. A separate trial found it matched calorie restriction but felt less restrictive. Experts advise a case-by-case approach given limited evidence.
Mar 25, 2026
Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.
Feb 23, 2026
A new Cochrane review of 22 randomized trials finds intermittent fasting produces little to no meaningful weight loss compared to traditional dietary advice or no intervention in overweight or obese adults.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
